CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net income	$ 26,704	$ 29,450
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred taxes	2,193	7,613
Depreciation of fixed assets and amortization of intangible assets	40,897	9,748
Amortization of debt issuance costs	2,053	1,310
Amortization of debt discount	1,412	11,401
Loss (gain) on disposal of fixed assets	193	(10)
Stock-based compensation	22,733	20,571
Changes in contingent consideration	(22,351)	(988)
Loss on investment	108	2,601
Changes in operating assets and liabilities:
Accounts receivable, net	5,213	(15,312)
Inventories, net	(2,038)	(615)
Prepaid expenses and other assets	(3,233)	(944)
Accounts payable	5,258	2,156
Accrued expenses and income taxes payable	(19,038)	(18,140)
Other liabilities	479	(964)
Payment of contingent consideration	0	(5,662)
Net cash provided by operating activities	60,583	42,215
Investing activities:
Purchases of fixed assets	(19,403)	(23,624)
Purchases of available-for-sale investments	(187,641)	(318,132)
Sales of available-for-sale investments	62,936	294,288
Payment of contingent consideration	(32,000)	0
Purchases of equity and debt investments	(12,750)	(14,220)
Sale of equity investment	0	9,057
Net cash used in investing activities	(188,858)	(52,631)
Financing activities:
Proceeds from exercises of stock options	21,881	15,997
Proceeds from shares issued under employee stock purchase plan	1,821	1,574
Repayment of Term loan B facility maturing December 2026	(9,375)	0
Payment of contingent consideration to MyoScience, Inc. securityholders	0	(1,338)
Net cash (used in) provided by financing activities	(335,242)	16,233
Net (decrease) increase in cash and cash equivalents	(463,517)	5,817
Cash and cash equivalents, beginning of period	585,578	99,957
Cash and cash equivalents, end of period	122,061	105,774
Supplemental cash flow information:
Cash paid for interest	14,686	3,586
Cash paid for income taxes, net of refunds	4,104	1,447
Non-cash investing and financing activities:
Issuance of common stock from conversion of 2022 convertible senior notes	3,040	0
Fixed assets included in accounts payable and accrued liabilities	2,454	8,096
Convertible Senior Notes Due 2022
Financing activities:
Repayment of convertible senior notes	(156,960)	0
Convertible Senior Notes Due 2024
Financing activities:
Repayment of convertible senior notes	$ (192,609)	$ 0